New drug on the horizon

[Guest guest]

This drug Ceflatonin is actually homoharringtonine or HHT. I was wondering

if any of the list members going to MD have come across this trial

drug or if we know anyone who is in the trial. From what I understand HHT

goes after a number of pathways including regulating apoptosis and

angiogenesis. This might be interesting since we all know it will take a

combination of drugs to " cure " CML.

Happy reading!

Cheers,

Cheryl-Anne

ChemGenex and Stragen Pharma Create Alliance to Accelerate Clinical

Development and Commercialization of Ceflatonin®

Monday June 27, 7:00 pm ET

MELBOURNE, Australia, and MENLO PARK, Calif. and GENEVA, June 27

/PRNewswire-FirstCall/ -- ChemGenex Pharmaceuticals Limited (ASX: CXS,

Nasdaq: CXSP), based in Melbourne, Australia and Menlo Park, California,

U.S.A., and Stragen Pharma S.A., based in Geneva, Switzerland, today

announced an international alliance to accelerate the clinical development

of ChemGenex's lead anti-cancer therapeutic, Ceflatonin®.

Ceflatonin® is currently in a Phase 2 Clinical Trial at the M.D.

Cancer Center in Houston, Texas treating chronic myeloid leukemia (CML)

patients who are resistant to Gleevec®. In addition to CML, Ceflatonin® has

established clinical activity in other hematological malignancies (blood

cell cancers) including myelodysplastic syndrome (MDS) and acute myeloid

leukemia (AML).

ChemGenex and Stragen will combine their respective strengths to pursue

clinical approval of Ceflatonin® in the US, Europe, Australia and other

territories. ChemGenex provides expertise in drug development and clinical

trial management while Stragen offers GMP manufacturing, distribution, and

marketing expertise.

Stragen has a patented manufacturing process for a semi-synthetic highly

purified form of homoharringtonine, the active molecule in Ceflatonin® and

has patented a suite of derivative molecules of homoharringtonine. ChemGenex

will exclusively license the global rights to Stragen's manufacturing

process and novel analogues under the terms of the alliance.

Under the terms of the alliance ChemGenex will be responsible for the global

clinical development of Ceflatonin®, as well as registration and marketing

in North America and Asia-Pacific. Stragen will be responsible for drug

production and global supply, as well as facilitating regulatory approvals

within Europe. In addition, ChemGenex will engage Stragen's established

European clinical network to accelerate the development of Ceflatonin®. Once

Ceflatonin® is approved in Europe, the alliance partners will market the

product under the ChemGenex brand. The eventual profit split of sales in

this territory will be shared ChemGenex 49%, Stragen 51%.

" The alliance with Stragen is a great opportunity for both companies to

capitalize on our respective strengths and to accelerate the development of

Ceflatonin® as a potential new therapy for chronic and acute leukemia, " said

Greg Collier, Ph.D., chief executive officer and managing director of

ChemGenex Pharmaceuticals. " This alliance expands ChemGenex's global

presence and gives us an outstanding partner with whom to progress

regulatory approval and eventual marketing of Ceflatonin® in Europe. "

" We are very pleased to be able to partner with ChemGenex on the development

of this promising anticancer drug, " said Jean-Luc Tetard, president of

Stragen Pharma. " Stragen's manufacturing capabilities and established

European drug distribution and marketing network, combined with ChemGenex's

strong clinical development and pharmaceutical marketing capabilities make

this an ideal partnership for the development and commercialization of

Ceflatonin®. "

Stratégie de Communication Med Summit Inc/Sommets Médical

FMC/FSC Stratégie de Communication, Planification et Coordination

CME/CHE Communication Strategy, Planning and Coordination Tel: (1)

514-782-2004 Fax (1) 514-782-8777

This e-mail and any attachments may contain confidential information. If you

are not the intended recipient, please notify the sender immediately by

return e-mail, delete this e-mail and destroy any copies. Any dissemination

or use of this information by a person other than the intended recipient is

unauthorized and may be illegal.Med Summit Inc. reserves the right to

monitor all e-mail communications through its networks for quality control

purposes. Ce message électronique et les fichiers qui y sont joints peuvent

contenir des renseignements confidentiels. Si vous n'êtes pas le

destinataire visé, veuillez en aviser immédiatement l'expéditeur en

répondant à ce message; effacez ensuite le message et détruisez toute copie.

La diffusion ou l'usage de ces renseignements par une personne autre que le

destinataire visé n'est pas autorisé et peut constituer un acte illégal. Med

Summit/Sommets Médical Inc. se réserve le droit de surveiller toutes les

communications transmises par courrier électronique par l'intermédiaire de

ses réseaux à des fins de contrôle de la qualité.